@article{Yongshuai2019,
  title = {PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.},
  author = {Jiang Yongshuai and Chen Ming and Nie Hong and Yuan Yuanyang},
  year = {2019},
  journal = {Human vaccines & immunotherapeutics},
  doi = {10.1080/21645515.2019.1571892},
  pmid = {30888929},
  url = {https://pubmed.ncbi.nlm.nih.gov/30888929/},
  abstract = {Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation. Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, and the development of anti-PD-1/PD-L1 antibodies has recently beco...},
}

@article{Weishi2024,
  title = {Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.},
  author = {Cheng Weishi and Kang Kai and Zhao Ailin and Wu Yijun},
  year = {2024},
  journal = {Journal of hematology & oncology},
  doi = {10.1186/s13045-024-01581-2},
  pmid = {39068460},
  url = {https://pubmed.ncbi.nlm.nih.gov/39068460/},
  abstract = {Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are some of the most common and promising targets in ICIs. Compared to ICI monotherapy, which occasionally demonstrates treatment resistance and limited efficacy, the dual blockade ...},
}

@article{Ramin2021,
  title = {PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.},
  author = {Hosseinzadeh Ramin and Feizisani Fahimeh and Shomali Navid and Abdelbasset Walid Kamal and Hemmatzadeh Maryam and Gholizadeh Navashenaq Jamshid and Jadidi-Niaragh Farhad and Bokov Dmitry O and Janebifam Morteza and Mohammadi Hamed},
  year = {2021},
  journal = {IUBMB life},
  doi = {10.1002/iub.2558},
  pmid = {34538007},
  url = {https://pubmed.ncbi.nlm.nih.gov/34538007/},
  abstract = {Immune checkpoint blockade therapy (ICBT) has become a successful cancer treatment approach in the field of cancer immunotherapy. Blockade of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) with monoclonal antibodies have been known as successful examples of cancer immunotherapy in recent years. Although ICBT has been shown to be beneficial in cancers, such benefits have only been seen in a portion of cancer patients. In this regard, enhancing the therapeutic effects of inhibitin...},
}

@article{Imran2019,
  title = {Intratumoral Tcf1},
  author = {Siddiqui Imran and Schaeuble Karin and Chennupati Vijaykumar and Fuertes Marraco Silvia A and Calderon-Copete Sandra and Pais Ferreira Daniela and Carmona Santiago J and Scarpellino Leonardo and Gfeller David and Pradervand Sylvain and Luther Sanjiv A and Speiser Daniel E and Held Werner},
  year = {2019},
  journal = {Immunity},
  doi = {10.1016/j.immuni.2018.12.021},
  pmid = {30635237},
  url = {https://pubmed.ncbi.nlm.nih.gov/30635237/},
  abstract = {Checkpoint blockade mediates a proliferative response of tumor-infiltrating CD8},
}

@article{Yang2020,
  title = {Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.},
  author = {Gao Yang and Nihira Naoe Taira and Bu Xia and Chu Chen and Zhang Jinfang and Kolodziejczyk Aleksandra and Fan Yizeng and Chan Ngai Ting and Ma Leina and Liu Jing and Wang Dong and Dai Xiaoming and Liu Huadong and Ono Masaya and Nakanishi Akira and Inuzuka Hiroyuki and North Brian J and Huang Yu-Han and Sharma Samanta and Geng Yan and Xu Wei and Liu X Shirley and Li Lei and Miki Yoshio and Sicinski Piotr and Freeman Gordon J and Wei Wenyi},
  year = {2020},
  journal = {Nature cell biology},
  doi = {10.1038/s41556-020-0562-4},
  pmid = {32839551},
  url = {https://pubmed.ncbi.nlm.nih.gov/32839551/},
  abstract = {Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive clinical outcomes for multiple tumours. However, only a subset of patients achieves durable responses, suggesting that the mechanisms of the immune checkpoint pathways are not completely understood. Here, we report that PD-L1 translocates from the plasma membrane into the nucleus through interactions with components of the en...},
}

@article{A2024,
  title = {Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges.},
  author = {Javed Sadique A and Najmi Asim and Ahsan Waquar and Zoghebi Khalid},
  year = {2024},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2024.1383456},
  pmid = {38660299},
  url = {https://pubmed.ncbi.nlm.nih.gov/38660299/},
  abstract = {The programmed death-1 receptor (PD-1) acts as a T-cell brake, and its interaction with ligand-1 (PD-L-1) interferes with signal transduction of the T-cell receptor. This leads to suppression of T-cell survival, proliferation, and activity in the tumor microenvironment resulting in compromised anticancer immunity. PD-1/PD-L-1 interaction blockade shown remarkable clinical success in various cancer immunotherapies. To date, most PD-1/PD-L-1 blockers approved for clinical use are monoclonal antibo...},
}

@article{Naomi2019,
  title = {Development of Cancer Immunotherapy Targeting the PD-1 Pathway.},
  author = {Kamimura Naomi and Wolf Alexander M and Iwai Yoshiko},
  year = {2019},
  journal = {Journal of Nippon Medical School = Nippon Ika Daigaku zasshi},
  doi = {10.1272/jnms.JNMS.2019_86-2},
  pmid = {30918149},
  url = {https://pubmed.ncbi.nlm.nih.gov/30918149/},
  abstract = {Immune checkpoint inhibitors are causing a paradigm shift in cancer treatment. Immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) dampen T cell activation to avoid autoimmunity and the destructive effects of an excessive inflammatory response. Immune checkpoint signaling can be exploited by tumors to escape host immune surveillance, and immune checkpoint inhibitors enhance antitumor immunity by releasing the brakes ...},
}

@article{N2024,
  title = {Interruption of the intratumor CD8},
  author = {Geels Shannon N and Moshensky Alexander and Sousa Rachel S and Murat Claire and Bustos Matias A and Walker Benjamin L and Singh Rima and Harbour Stacey N and Gutierrez Giselle and Hwang Michael and Mempel Thorsten R and Weaver Casey T and Nie Qing and Hoon Dave S B and Ganesan Anand K and Othy Shivashankar and Marangoni Francesco},
  year = {2024},
  journal = {Cancer cell},
  doi = {10.1016/j.ccell.2024.05.013},
  pmid = {38861924},
  url = {https://pubmed.ncbi.nlm.nih.gov/38861924/},
  abstract = {PD-1 blockade unleashes potent antitumor activity in CD8},
}

@article{Arash2019,
  title = {PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.},
  author = {Salmaninejad Arash and Valilou Saeed Farajzadeh and Shabgah Arezoo Gowhari and Aslani Saeed and Alimardani Malihe and Pasdar Alireza and Sahebkar Amirhossein},
  year = {2019},
  journal = {Journal of cellular physiology},
  doi = {10.1002/jcp.28358},
  pmid = {30784085},
  url = {https://pubmed.ncbi.nlm.nih.gov/30784085/},
  abstract = {Over the course of past few years, cancer immunotherapy has been accompanied with promising results. However, preliminary investigations with respect to immunotherapy concentrated mostly on targeting the immune checkpoints, nowadays, emerge as the most efficient strategy to raise beneficial antitumor immune responses. Programmed cell death protein 1 (PD-1) plays an important role in subsiding immune responses and promoting self-tolerance through suppressing the activity of T cells and promoting ...},
}

@article{Luis2020,
  title = {Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.},
  author = {Córdova-Bahena Luis and Velasco-Velázquez Marco A},
  year = {2020},
  journal = {Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion},
  doi = {10.24875/RIC.20000341},
  pmid = {33079077},
  url = {https://pubmed.ncbi.nlm.nih.gov/33079077/},
  abstract = {Programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand-1 (PD-L1), play key roles in the suppression of the cytotoxic activity of T cells. PD-L1 is overexpressed on various types of cancer cells, leading to immune evasion. In the past decade, therapeutic antibodies that target the PD-1/PD-L1 axis have been developed to inhibit the immune suppression triggered by these two proteins. At present, five antibodies (two anti-PD-1 and three anti-PD-L1) have received approval by r...},
}

@article{Sema2019,
  title = {Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1},
  author = {Kurtulus Sema and Madi Asaf and Escobar Giulia and Klapholz Max and Nyman Jackson and Christian Elena and Pawlak Mathias and Dionne Danielle and Xia Junrong and Rozenblatt-Rosen Orit and Kuchroo Vijay K and Regev Aviv and Anderson Ana C},
  year = {2019},
  journal = {Immunity},
  doi = {10.1016/j.immuni.2018.11.014},
  pmid = {30635236},
  url = {https://pubmed.ncbi.nlm.nih.gov/30635236/},
  abstract = {An improved understanding of the anti-tumor CD8},
}

@article{Qiyue2025,
  title = {Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.},
  author = {Sun Qiyue and Hong Senlian},
  year = {2025},
  journal = {International journal of molecular sciences},
  doi = {10.3390/ijms26031238},
  pmid = {39941004},
  url = {https://pubmed.ncbi.nlm.nih.gov/39941004/},
  abstract = {Immune checkpoint blockade therapy, represented by anti-PD-1/PD-L1 monoclonal antibodies, has significantly changed the immunotherapy landscape. However, the treatment is still limited by unsatisfactory response rates, immune-related adverse effects, and drug resistance. Current studies have established that glycosylation, a common post-translational modification, is crucial in promoting cancer progression and immune invasion. Targeting aberrant glycosylation in cancers presents precision medici...},
}

@article{Peifu2018,
  title = {Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy.},
  author = {Jiao Peifu and Geng Qiaohong and Jin Peng and Su Gaoxing and Teng Houyun and Dong Jinlong and Yan Bing},
  year = {2018},
  journal = {Current pharmaceutical design},
  doi = {10.2174/1381612824666181112114958},
  pmid = {30417781},
  url = {https://pubmed.ncbi.nlm.nih.gov/30417781/},
  abstract = {Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. Nevertheless, therapeutic antibodies also exhibit several disadvantages such as low tumor penetration, difficulty in crossing physiological barriers, lacking oral bioavailability, high manufacturing costs, inaccessible to intracellular targets, immunogenicity, ...},
}

@article{Songyu2024,
  title = {Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways.},
  author = {Shen Songyu and Hong Yihan and Huang Jiajun and Qu Xiaosheng and Sooranna Suren Rao and Lu Sheng and Li Tian and Niu Bing},
  year = {2024},
  journal = {Cytokine & growth factor reviews},
  doi = {10.1016/j.cytogfr.2024.08.001},
  pmid = {39179486},
  url = {https://pubmed.ncbi.nlm.nih.gov/39179486/},
  abstract = {Tumor immunotherapy has garnered considerable attention, emerging as a new standard of care in cancer treatment. The conventional targets, such as VEGF and EGFR, have been extended to others including BRAF and PD-1/PD-L1, which have shown significant potential in recent cancer treatments. This review aims to succinctly overview the impact and mechanisms of therapies that modulate PD-1/PD-L1 expression by targeting VEGF, EGFR, LAG-3, CTLA-4 and BRAF. We investigated how modulation of PD-1/PD-L1 e...},
}

@article{Yi2019,
  title = {Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.},
  author = {Zheng Yi and Wang Tingting and Tu Xiaoxuan and Huang Yun and Zhang Hangyu and Tan Di and Jiang Weiqin and Cai Shunfeng and Zhao Peng and Song Ruixue and Li Peilu and Qin Nan and Fang Weijia},
  year = {2019},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1186/s40425-019-0650-9},
  pmid = {31337439},
  url = {https://pubmed.ncbi.nlm.nih.gov/31337439/},
  abstract = {BACKGROUND: Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we report the dynamic variation characteristics and specificities of the gut microbiome during anti-PD-1 immunotherapy in HCC using metagenomic sequencing. RESULTS: Fecal samples from patients responding to immun...},
}

@article{Alok2021,
  title = {Immune metabolism in PD-1 blockade-based cancer immunotherapy.},
  author = {Kumar Alok and Chamoto Kenji},
  year = {2021},
  journal = {International immunology},
  doi = {10.1093/intimm/dxaa046},
  pmid = {32622347},
  url = {https://pubmed.ncbi.nlm.nih.gov/32622347/},
  abstract = {Energy metabolism plays an important role in proliferating cells. Recent reports indicate that metabolic regulation or metabolic products can control immune cell differentiation, fate and reactions. Cancer immunotherapy based on blockade of programmed cell death protein 1 (PD-1) has been used worldwide, but a significant fraction of patients remain unresponsive. Therefore, clarifying the mechanisms and overcoming the unresponsiveness are urgent issues. Because cancer immunity consists of interac...},
}

@article{Junyu2017,
  title = {PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.},
  author = {Long Junyu and Lin Jianzhen and Wang Anqiang and Wu Liangcai and Zheng Yongchang and Yang Xiaobo and Wan Xueshuai and Xu Haifeng and Chen Shuguang and Zhao Haitao},
  year = {2017},
  journal = {Journal of hematology & oncology},
  doi = {10.1186/s13045-017-0511-2},
  pmid = {28774337},
  url = {https://pubmed.ncbi.nlm.nih.gov/28774337/},
  abstract = {Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have led to significant advances in the treatment of GI cancer patients, overall survival is still low. Therefore, alternative strategies must be identified to improve patient outcomes. In the tumor microenvironment, tumor cells can escape the host immune response through the interaction of PD-...},
}

@article{Jianheng2024,
  title = {Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).},
  author = {Wu Jianheng and Wang Nannan},
  year = {2024},
  journal = {Molecular medicine reports},
  doi = {10.3892/mmr.2024.13344},
  pmid = {39364736},
  url = {https://pubmed.ncbi.nlm.nih.gov/39364736/},
  abstract = {Glioblastoma (GBM) is the most common central nervous system malignancy in adults. GBM may be classified as grade IV diffuse astrocytoma according to the 2021 World Health Organization revised classification of central nervous system tumors, which means it is the most aggressive, invasive, undifferentiated type of tumor. Immune checkpoint blockade (ICB), particularly anti‑programmed cell death protein‑1 (PD‑1)/PD‑1 ligand‑1 immunotherapy, has been confirmed to be successful across several tumor ...},
}

@article{K2019,
  title = {PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.},
  author = {Dermani Fatemeh K and Samadi Pouria and Rahmani Golebagh and Kohlan Alisa K and Najafi Rezvan},
  year = {2019},
  journal = {Journal of cellular physiology},
  doi = {10.1002/jcp.27172},
  pmid = {30191996},
  url = {https://pubmed.ncbi.nlm.nih.gov/30191996/},
  abstract = {Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. One of the most critical checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1). PD-1 is highly expressed by activated T cells, B cells, dendritic cells, and natura...},
}

@article{Irma2019,
  title = {Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.},
  author = {Herrera-Camacho Irma and Anaya-Ruiz Maricruz and Perez-Santos Martin and Millán-Pérez Peña Lourdes and Bandala Cindy and Landeta Gerardo},
  year = {2019},
  journal = {Expert opinion on therapeutic patents},
  doi = {10.1080/13543776.2019.1637422},
  pmid = {31241380},
  url = {https://pubmed.ncbi.nlm.nih.gov/31241380/},
}
